 |
|
|
| |
Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin for the Treatment of Patients With Chronic HCV Genotype 1 Infection:
An Analysis of the Phase 3 ION Trials
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Saleh Alqahtani,1 NezamAfdhal,2 Stefan Zeuzem,3 Stuart Gordon,4 Alessandra Mangia,5 Paul Kwo,6 Jenny C. Yang,7 Xiao Ding,7 Phillip S. Pang,7 John G. McHutchison,7 Patrick Marcellin,8 Kris Kowdley,9 Mark Sulkowski1
1Johns Hopkins Medical Center, Baltimore, MD; 2Beth Israel Deaconess Medical Center, Boston, MA; 3Johann Wolfgang Goethe University, Frankfurt, Germany; 4Henry Ford Health System, Detroit, MI; 5Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy;
6Indiana University School of Medicine, Indianapolis, IN; 7Gilead Sciences, Inc., Foster City, CA; 8Centre Hospitalier Universitaire Beaujon, Clichy-sous-Bois, France; 9Virginia Mason Medical Center, Seattle, WA
|
| |
|
|
|
|
|
